Session: 711. Cell Collection and Manufacturing of HSPCs, CAR-T Cells, and Other Cellular Therapy Products: Poster I
Hematology Disease Topics & Pathways:
Adverse Events
Methods - We performed a retrospective cohort study in adult patients diagnosed with multiple myeloma who received motixafortide for ASCT mobilization between January 1, 2024 and July 1, 2024. Our first 3 patients received the recommended premedication protocol which is oral doses of diphenhydramine 25 to 50 mg, famotidine 20 mg, montelukast 10 mg, and acetaminophen 650 mg, approximately 60 minutes before injection. Patients also received loratadine 10 mg daily beginning on the day of G-CSF initiation, 3 days prior to motixafortide. The following 5 patients received oral dexamethasone 4 mg in attempts to curtail AEs. Subsequently, 16 patients were started on MF-DEX, which consisted of starting famotidine 20 mg, montelukast 10 mg on the day of growth factor administration and continuing until 1 day after collection (5 days total), along with IV dexamethasone 8 mg added onto the standard premedications listed previously. Hypersensitivity AEs included all events recorded in MedDRA terms of urticaria, pruritus, flushing, erythema, rash, hypersensitivity or anaphylaxis. Injection site AEs were graded using CTCAE criteria.
Results - All patients that received the standard premedication had injection site reactions. Patients that received the standard premedication had 66.6% (N=2/3) grade 2 or greater injection site and hypersensitivity reactions. After the interim addition of dexamethasone 4 mg PO there was a reduction of grade 2 injection site reaction to 40% (N=2/5) and no grade 3 reactions. With the premedication strategy of MF-DEX, less patients, 5.8% (N=1/17) and 17.6% (N=3/17) had grade 2 or greater injection site and hypersensitivity reactions respectively. All patients reviewed collected 6x10 6 CD34+ cells/kg stem cells with no difference seen on collection time in both groups.
Conclusions - MF-DEX decreased grade 2 hypersensitivity reactions in patients receiving motixafortide. Although patients who received the standard premedications had no grade 4 events and all AEs were manageable with supportive care, it was a clear burden to our patients and nursing staff. After adoption of MF-DEX our center has seen less hypersensitivity reactions and patient outcomes have improved.
Disclosures: Abdelmessieh: Sobi: Consultancy; Abbive: Consultancy. Fung: sobi: Consultancy, Speakers Bureau; Johnson and Johnson: Consultancy, Speakers Bureau; Astra-Zeneca: Consultancy, Speakers Bureau; Incyte: Consultancy, Speakers Bureau; Gilead: Consultancy, Speakers Bureau; Bioline: Consultancy, Speakers Bureau. Varshavsky-Yanovsky: Janssen: Consultancy, Other: Board of Directors/Advisory Committee; BMS: Consultancy; Pfizer: Consultancy.